The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Castration-resistant Prostate Cancer Drugs Market Research Report 2025

Global Castration-resistant Prostate Cancer Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1733069

No of Pages : 94

Ask Your Query

Synopsis

Highlights
The global Castration-resistant Prostate Cancer Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Castration-resistant Prostate Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Castration-resistant Prostate Cancer Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Castration-resistant Prostate Cancer Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Castration-resistant Prostate Cancer Drugs include Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi and Hansoh, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Castration-resistant Prostate Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-resistant Prostate Cancer Drugs.
The Castration-resistant Prostate Cancer Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Castration-resistant Prostate Cancer Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castration-resistant Prostate Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

  • Pfizer
  • Astellas
  • Janssen
  • Astrazeneca
  • Bayer
  • Hengrui
  • Cttq
  • Sanofi
  • Hansoh
  • Clovis Oncology
  • Zhendong Pharmaceutical
  • Merck

Segment by Type

  • Oral
  • Intravenous Injection
  • Others

Segment by Application

  • Hospital
  • Specialty Clinic
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration-resistant Prostate Cancer Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Intravenous Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Castration-resistant Prostate Cancer Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castration-resistant Prostate Cancer Drugs Market Perspective (2018-2029)
2.2 Castration-resistant Prostate Cancer Drugs Growth Trends by Region
2.2.1 Global Castration-resistant Prostate Cancer Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Castration-resistant Prostate Cancer Drugs Historic Market Size by Region (2018-2023)
2.2.3 Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Region (2024-2029)
2.3 Castration-resistant Prostate Cancer Drugs Market Dynamics
2.3.1 Castration-resistant Prostate Cancer Drugs Industry Trends
2.3.2 Castration-resistant Prostate Cancer Drugs Market Drivers
2.3.3 Castration-resistant Prostate Cancer Drugs Market Challenges
2.3.4 Castration-resistant Prostate Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castration-resistant Prostate Cancer Drugs Players by Revenue
3.1.1 Global Top Castration-resistant Prostate Cancer Drugs Players by Revenue (2018-2023)
3.1.2 Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Castration-resistant Prostate Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Castration-resistant Prostate Cancer Drugs Revenue
3.4 Global Castration-resistant Prostate Cancer Drugs Market Concentration Ratio
3.4.1 Global Castration-resistant Prostate Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castration-resistant Prostate Cancer Drugs Revenue in 2022
3.5 Castration-resistant Prostate Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Castration-resistant Prostate Cancer Drugs Product Solution and Service
3.7 Date of Enter into Castration-resistant Prostate Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Castration-resistant Prostate Cancer Drugs Breakdown Data by Type
4.1 Global Castration-resistant Prostate Cancer Drugs Historic Market Size by Type (2018-2023)
4.2 Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Type (2024-2029)
5 Castration-resistant Prostate Cancer Drugs Breakdown Data by Application
5.1 Global Castration-resistant Prostate Cancer Drugs Historic Market Size by Application (2018-2023)
5.2 Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Castration-resistant Prostate Cancer Drugs Market Size (2018-2029)
6.2 North America Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023)
6.4 North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castration-resistant Prostate Cancer Drugs Market Size (2018-2029)
7.2 Europe Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023)
7.4 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size (2018-2029)
8.2 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castration-resistant Prostate Cancer Drugs Market Size (2018-2029)
9.2 Latin America Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023)
9.4 Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size (2018-2029)
10.2 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Introduction
11.1.4 Pfizer Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Astellas
11.2.1 Astellas Company Detail
11.2.2 Astellas Business Overview
11.2.3 Astellas Castration-resistant Prostate Cancer Drugs Introduction
11.2.4 Astellas Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.2.5 Astellas Recent Development
11.3 Janssen
11.3.1 Janssen Company Detail
11.3.2 Janssen Business Overview
11.3.3 Janssen Castration-resistant Prostate Cancer Drugs Introduction
11.3.4 Janssen Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.3.5 Janssen Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Introduction
11.4.4 AstraZeneca Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.4.5 AstraZeneca Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Castration-resistant Prostate Cancer Drugs Introduction
11.5.4 Bayer Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.5.5 Bayer Recent Development
11.6 Hengrui
11.6.1 Hengrui Company Detail
11.6.2 Hengrui Business Overview
11.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Introduction
11.6.4 Hengrui Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.6.5 Hengrui Recent Development
11.7 CTTQ
11.7.1 CTTQ Company Detail
11.7.2 CTTQ Business Overview
11.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Introduction
11.7.4 CTTQ Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.7.5 CTTQ Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Introduction
11.8.4 Sanofi Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.8.5 Sanofi Recent Development
11.9 Hansoh
11.9.1 Hansoh Company Detail
11.9.2 Hansoh Business Overview
11.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Introduction
11.9.4 Hansoh Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.9.5 Hansoh Recent Development
11.10 Clovis Oncology
11.10.1 Clovis Oncology Company Detail
11.10.2 Clovis Oncology Business Overview
11.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Introduction
11.10.4 Clovis Oncology Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.10.5 Clovis Oncology Recent Development
11.11 Zhendong Pharmaceutical
11.11.1 Zhendong Pharmaceutical Company Detail
11.11.2 Zhendong Pharmaceutical Business Overview
11.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Introduction
11.11.4 Zhendong Pharmaceutical Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.11.5 Zhendong Pharmaceutical Recent Development
11.12 Merck
11.12.1 Merck Company Detail
11.12.2 Merck Business Overview
11.12.3 Merck Castration-resistant Prostate Cancer Drugs Introduction
11.12.4 Merck Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
11.12.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Oral
Table 3. Key Players of Intravenous Injection
Table 4. Key Players of Others
Table 5. Global Castration-resistant Prostate Cancer Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Castration-resistant Prostate Cancer Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Castration-resistant Prostate Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Castration-resistant Prostate Cancer Drugs Market Share by Region (2018-2023)
Table 9. Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Castration-resistant Prostate Cancer Drugs Market Share by Region (2024-2029)
Table 11. Castration-resistant Prostate Cancer Drugs Market Trends
Table 12. Castration-resistant Prostate Cancer Drugs Market Drivers
Table 13. Castration-resistant Prostate Cancer Drugs Market Challenges
Table 14. Castration-resistant Prostate Cancer Drugs Market Restraints
Table 15. Global Castration-resistant Prostate Cancer Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Castration-resistant Prostate Cancer Drugs Market Share by Players (2018-2023)
Table 17. Global Top Castration-resistant Prostate Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-resistant Prostate Cancer Drugs as of 2022)
Table 18. Ranking of Global Top Castration-resistant Prostate Cancer Drugs Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Castration-resistant Prostate Cancer Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Castration-resistant Prostate Cancer Drugs Product Solution and Service
Table 22. Date of Enter into Castration-resistant Prostate Cancer Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Castration-resistant Prostate Cancer Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Type (2018-2023)
Table 26. Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Type (2024-2029)
Table 28. Global Castration-resistant Prostate Cancer Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Application (2018-2023)
Table 30. Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Application (2024-2029)
Table 32. North America Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Castration-resistant Prostate Cancer Drugs Product
Table 50. Pfizer Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Astellas Company Detail
Table 53. Astellas Business Overview
Table 54. Astellas Castration-resistant Prostate Cancer Drugs Product
Table 55. Astellas Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 56. Astellas Recent Development
Table 57. Janssen Company Detail
Table 58. Janssen Business Overview
Table 59. Janssen Castration-resistant Prostate Cancer Drugs Product
Table 60. Janssen Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 61. Janssen Recent Development
Table 62. AstraZeneca Company Detail
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Castration-resistant Prostate Cancer Drugs Product
Table 65. AstraZeneca Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 66. AstraZeneca Recent Development
Table 67. Bayer Company Detail
Table 68. Bayer Business Overview
Table 69. Bayer Castration-resistant Prostate Cancer Drugs Product
Table 70. Bayer Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 71. Bayer Recent Development
Table 72. Hengrui Company Detail
Table 73. Hengrui Business Overview
Table 74. Hengrui Castration-resistant Prostate Cancer Drugs Product
Table 75. Hengrui Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 76. Hengrui Recent Development
Table 77. CTTQ Company Detail
Table 78. CTTQ Business Overview
Table 79. CTTQ Castration-resistant Prostate Cancer Drugs Product
Table 80. CTTQ Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 81. CTTQ Recent Development
Table 82. Sanofi Company Detail
Table 83. Sanofi Business Overview
Table 84. Sanofi Castration-resistant Prostate Cancer Drugs Product
Table 85. Sanofi Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 86. Sanofi Recent Development
Table 87. Hansoh Company Detail
Table 88. Hansoh Business Overview
Table 89. Hansoh Castration-resistant Prostate Cancer Drugs Product
Table 90. Hansoh Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 91. Hansoh Recent Development
Table 92. Clovis Oncology Company Detail
Table 93. Clovis Oncology Business Overview
Table 94. Clovis Oncology Castration-resistant Prostate Cancer Drugs Product
Table 95. Clovis Oncology Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 96. Clovis Oncology Recent Development
Table 97. Zhendong Pharmaceutical Company Detail
Table 98. Zhendong Pharmaceutical Business Overview
Table 99. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product
Table 100. Zhendong Pharmaceutical Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 101. Zhendong Pharmaceutical Recent Development
Table 102. Merck Company Detail
Table 103. Merck Business Overview
Table 104. Merck Castration-resistant Prostate Cancer Drugs Product
Table 105. Merck Revenue in Castration-resistant Prostate Cancer Drugs Business (2018-2023) & (US$ Million)
Table 106. Merck Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Castration-resistant Prostate Cancer Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Castration-resistant Prostate Cancer Drugs Market Share by Type: 2022 VS 2029
Figure 3. Oral Features
Figure 4. Intravenous Injection Features
Figure 5. Others Features
Figure 6. Global Castration-resistant Prostate Cancer Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Castration-resistant Prostate Cancer Drugs Market Share by Application: 2022 VS 2029
Figure 8. Hospital Case Studies
Figure 9. Specialty Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Castration-resistant Prostate Cancer Drugs Report Years Considered
Figure 12. Global Castration-resistant Prostate Cancer Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Castration-resistant Prostate Cancer Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Castration-resistant Prostate Cancer Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Castration-resistant Prostate Cancer Drugs Market Share by Players in 2022
Figure 16. Global Top Castration-resistant Prostate Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-resistant Prostate Cancer Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Castration-resistant Prostate Cancer Drugs Revenue in 2022
Figure 18. North America Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Castration-resistant Prostate Cancer Drugs Market Share by Country (2018-2029)
Figure 20. United States Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Castration-resistant Prostate Cancer Drugs Market Share by Country (2018-2029)
Figure 24. Germany Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Share by Region (2018-2029)
Figure 32. China Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Castration-resistant Prostate Cancer Drugs Market Share by Country (2018-2029)
Figure 40. Mexico Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Share by Country (2018-2029)
Figure 44. Turkey Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Pfizer Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 47. Astellas Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 48. Janssen Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 49. AstraZeneca Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 50. Bayer Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 51. Hengrui Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 52. CTTQ Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 53. Sanofi Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 54. Hansoh Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 55. Clovis Oncology Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 56. Zhendong Pharmaceutical Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 57. Merck Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock